Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older

Stone, 2001, Postremission therapy in older patients with de novo acute myeloid leukemia, Blood, 98, 548, 10.1182/blood.V98.3.548

Anderson, 2002, Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin, Blood, 100, 3869, 10.1182/blood-2001-12-0354

Godwin, 1998, A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia, Blood, 91, 3607, 10.1182/blood.V91.10.3607

Goldstone, 2001, Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients, Blood, 98, 1302, 10.1182/blood.V98.5.1302

Gupta, 2005, Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy, Cancer, 103, 2082, 10.1002/cncr.21006

Lowenberg, 1997, Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia, Blood, 90, 2952

Rowe, 2004, A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia, Blood, 103, 479, 10.1182/blood-2003-05-1686

Hiddemann, 1999, Management of acute myeloid leukemia in elderly patients, J Clin Oncol, 17, 3569, 10.1200/JCO.1999.17.11.3569

Giralt, 2004, Bone marrow transplant in myelodysplastic syndromes, Curr Hematol Rep, 3, 165

Yanada, 2005, Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission, Cancer, 103, 1652, 10.1002/cncr.20945

Chakraverty, 2002, Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen, Blood, 99, 1071, 10.1182/blood.V99.3.1071

Corradini, 2002, Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies, Blood, 99, 75, 10.1182/blood.V99.1.75

Giralt, 1997, Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy, Blood, 89, 4531, 10.1182/blood.V89.12.4531

Slavin, 1998, Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases, Blood, 91, 756, 10.1182/blood.V91.3.756

Martino, 2001, Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning, Br J Haematol, 115, 653, 10.1046/j.1365-2141.2001.03153.x

McSweeney, 2001, Hematopoietic cell transplantation in older patients with hematologic malignancies, Blood, 97, 3390, 10.1182/blood.V97.11.3390

Baron, 2005, Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning, J Clin Oncol, 23, 1993, 10.1200/JCO.2005.08.136

Taussig, 2003, Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting, J Clin Oncol, 21, 3060, 10.1200/JCO.2003.02.057

Ho, 2004, Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning, Blood, 104, 1616, 10.1182/blood-2003-12-4207

Malladi, 2004, Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies, Eur J Haematol, 73, 85, 10.1111/j.1600-0609.2004.00266.x

Hamaki, 2004, Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies, Bone Marrow Transplant, 33, 891, 10.1038/sj.bmt.1704477

Gomez-Nunez, 2004, Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning, Bone Marrow Transplant, 33, 477, 10.1038/sj.bmt.1704379

Sayer, 2003, Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia, Bone Marrow Transplant, 31, 1089, 10.1038/sj.bmt.1704062

Platzbecker, 2003, Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases, Ann Hematol, 82, 463, 10.1007/s00277-003-0680-7

Kroger, 2003, Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia, Ann Hematol, 82, 336, 10.1007/s00277-003-0654-9

Feinstein, 2003, Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission, Br J Haematol, 120, 281, 10.1046/j.1365-2141.2003.04057.x

Martino, 2002, Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes, Blood, 100, 2243, 10.1182/blood-2002-02-0400

Shapira, 2004, Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients, Bone Marrow Transplant, 34, 155, 10.1038/sj.bmt.1704540

Bertz, 2003, Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia, J Clin Oncol, 21, 1480, 10.1200/JCO.2003.09.110

Greenberg, 1997, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, 2079, 10.1182/blood.V89.6.2079

Nollet, 2001, Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing, Bone Marrow Transplant, 28, 511, 10.1038/sj.bmt.1703162

Glucksberg, 1974, Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors, Transplantation, 18, 295, 10.1097/00007890-197410000-00001

Shulman, 1980, Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients, Am J Med, 69, 204, 10.1016/0002-9343(80)90380-0

Flowers, 2005, Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning, Bone Marrow Transplant, 35, 277, 10.1038/sj.bmt.1704767

Bearman, 1988, Regimen-related toxicity in patients undergoing bone marrow transplantation, J Clin Oncol, 6, 1562, 10.1200/JCO.1988.6.10.1562

Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452

Gooley, 1999, Estimation of failure probabilities in the presence of competing risks, Stat Med, 18, 695, 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O

Wallen, 2005, Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older, J Clin Oncol, 23, 3439, 10.1200/JCO.2005.05.694

Mielcarek, 2003, Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation, Blood, 102, 756, 10.1182/blood-2002-08-2628

Solomon, 2005, Selective depletion of alloreactive donor lymphocytes—a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation, Blood, 106, 1123, 10.1182/blood-2005-01-0393

Wulf, 2003, Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation, Blood, 101, 2434, 10.1182/blood-2002-08-2379

Bacigalupo, 2005, Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis, Bone Marrow Transplant, 35, 225, 10.1038/sj.bmt.1704758

Mohty, 2003, Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen, Leukemia, 17, 2168, 10.1038/sj.leu.2403105

Meijer, 2004, Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, Transpl Infect Dis, 6, 171, 10.1111/j.1399-3062.2004.00075.x

Daly, 2003, Nonmyeloablative bone marrow transplantation, Biol Blood Marrow Transplant, 9, 373, 10.1016/S1083-8791(03)00100-9

Kiss, 2004, Bone marrow aspirates as part of routine donor assessment for allogeneic blood and marrow transplantation can reveal presence of occult hematological malignancies in otherwise asymptomatic individuals, Bone Marrow Transplant, 33, 855, 10.1038/sj.bmt.1704430

Gupta, 2004, The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission, Bone Marrow Transplant, 33, 397, 10.1038/sj.bmt.1704368

Spyridonidis, 2005, Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies, Blood, 105, 4147, 10.1182/blood-2005-01-0196

Cutler, 2004, A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes, Blood, 104, 579, 10.1182/blood-2004-01-0338

Silverman, 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome, J Clin Oncol, 20, 2429, 10.1200/JCO.2002.04.117

Kornblith, 2002, Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial, J Clin Oncol, 20, 2441, 10.1200/JCO.2002.04.044

van den Bosch, 2004, The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes, Leuk Res, 28, 785, 10.1016/j.leukres.2003.11.016